Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could genetic testing for prostate cancer transform routine care? a study asks patients and doctors

NCT ID NCT07741929

Knowledge-focused Sponsor: Royal Marsden NHS Foundation Trust Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 03, 2026 · Last updated Aug 04, 2026 · Updated 1 time

Summary

This study explores how patients and healthcare providers view the use of genetic risk profiling for prostate cancer in everyday clinical practice. Through interviews, researchers aim to understand the benefits, challenges, and needs associated with receiving and delivering genetic risk results. The findings may help guide how such testing could be better integrated into routine care, ensuring it is practical and supportive for all involved.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Qualitative interviews
What this could lead to
If successful, this study could help shape how genetic risk profiling for prostate cancer is integrated into routine clinical care, improving patient education, support, and clinical guidelines.
What could go wrong
This is a small, interview-based study, so its findings may not represent all perspectives. It does not test a treatment or intervention, so it cannot directly change patient outcomes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 40 people

The number the study aims to enrol. It can still change while the study runs.

Started

May 2026

Expected to finish

Aug 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Patients who have undergone and received a genetic risk profiling result for prostate cancer and healthcare providers who have delivered a genetic risk profiling result for prostate cancer

Ages

18 to 100 years

Sex

Male participants only

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Individuals assigned male at birth who are aged 18 and over and who have capacity to consent * Patients who have undergone genetic risk profiling for prostate cancer and have received their results * Individuals from diverse backgrounds (age, ethnicity, risk status, etc) * Healthcare providers who have delivered a genetic risk profiling result for prostate cancer Exclusion Criteria: * Individuals who lack capacity to consent * Individuals deemed unsuitable to recruit based on their poor performance status or current medical condition

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Prostate cancer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

prostate cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Prostate cancer

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • The Royal Marsden Hospital (Sutton and Chelsea)

    RECRUITING

    London, SM2 5PT, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.